Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Plus de 40000 produits accessibles à 0€ de frais de courtage
Découvrir Boursomarkets
Fermer

Transgene unveils myvac (TM), an individualized immunotherapy against solid tumors
information fournie par Boursorama 24/09/2018 à 17:45

Transgene unveils myvac (TM), an individualized immunotherapy against solid tumors

•myvac (TM) is a viral vector-based, individualized immunotherapy that has been developed to target solid tumors
•myvac (TM) stimulates the patient’s immune system to recognize and destroy tumors using their own cancer specific genetic mutations
•myvac (TM) is a highly innovative approach that combines the use of the tumor’s neoantigens with the Transgene’s viral vector expertise
•First patient to be treated in 2019

.../...

Valeurs associées

0,71 EUR Euronext Paris 0,00%

0 commentaire

Signaler le commentaire

Fermer

Mes listes

Cette liste ne contient aucune valeur.